Evaluation of Anti-Xa Target Attainment with Prophylactic Enoxaparin Dosing Regimens for Venous Thromboembolism Prophylaxis in Morbidly Obese Patients
Subcutaneous enoxaparin has been shown to reduce the risk of venous thromboembolism (VTE) among hospitalized patients. However, alternative enoxaparin dosing strategies may be necessary in morbid obesity. The objective of this study was to assess the rate of target anti-Xa attainment with three enox...
Saved in:
Main Authors: | Andrew Sabers (Author), Emilie Langenhan (Author), Sean N. Avedissian (Author), Brandon Reynolds (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
by: Seeba Zachariah, et al.
Published: (2020) -
The use of enoxaparin as venous thromboembolism prophylaxis in bariatric surgery: A retrospective cohort study
by: Esraa Altawil, et al.
Published: (2022) -
Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
by: Tahaineh L, et al.
Published: (2018) -
Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
by: Aliya Abdulla, et al.
Published: (2023) -
How enoxaparin underdosing and sex contribute to achieving therapeutic anti-Xa levels
by: Alexander Tinchon, et al.
Published: (2024)